Chemotherapy Induced Nausea and Vomiting Drugs Market Size, Industry Trends, Share and Forecast 2022-2028
The global chemotherapy-induced nausea and vomiting drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The term chemotherapy-induced nausea and vomiting includes emesis and nausea, which can involve a loss of appetite and result in the decreased oral intake of fluids and calories. Therefore, for the management of such conditions, the demand for chemotherapy-induced nausea and vomiting drugs is likely to grow in the near future. Further, the growing geriatric population along with the rising prevalence of cancer are acting as the pivotal factors responsible for the increased demand for these drugs.
The global chemotherapy-induced
nausea and vomiting drugs market is also driven by extensive R&D along with
new FDA approvals. For instance, in April 2021, Caplin Steriles has been
granted final approval from the US FDA for its abbreviated new drug application
(ANDA) prochlorperazine edisylate injection USP, 10 mg/2 mL (5 mg/mL) vials.
Prochlorperazine edisylate injection is a drug that is indicated for the
control of severe nausea and vomiting.
To Request a Sample of our Report on Chemotherapy
Induced Nausea and Vomiting Drugs Market:
https://www.omrglobal.com/request-sample/chemotherapy-induced-nausea-and-vomiting-drugs-market
Some major key players in the market include Novartis International AG, F.
Hoffman La-Roche AG, and Merck & Co., Inc., among others. The market
players are contributing significantly to the growth of the market by the
adoption of various strategies including mergers and acquisitions, geographical
expansion, partnerships and collaborations, and new product launches, to stay
competitive in the market. For instance, in November 2021, Heron Therapeutics,
Inc. announced the submission of its New Drug Application (NDA) to the US Food
and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion.
HTX-019 injectable emulsion is intended to be used for the prevention of
postoperative nausea and vomiting (PONV) in adults.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2022-2028
Segment Covered-
·
By Type
·
By Therapy
·
By Drug Type
Regions covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape: Novartis International AG, F. Hoffman La-Roche AG,
and Merck & Co., Inc., among others.
(Get 15% Discount on Buying this Report)
A
full Report of Chemotherapy Induced Nausea and Vomiting Drugs Market is
Available @ https://www.omrglobal.com/industry-reports/chemotherapy-induced-nausea-and-vomiting-drugs-market
Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Report by
Segment
By Type
·
Acute Emesis
·
Delayed Emesis
·
Anticipatory Emesis
·
Refractory Emesis
By Therapy
·
Nk-1 Receptor Antagonist
·
Serotonin Receptor Antagonist
·
Others
By Drug Type
·
Branded
·
Generics
Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Report by
Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment